Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo Us Biotech Limited reported annual revenue of Rs 1,104.39 crore (up 6.6% from Rs 1,036.33 crore in FY25). Net profit declined significantly to Rs 131.23 lakh from Rs 162.67 lakh in the prior year, a drop of about 19%. Despite profitability, operating cash flow was negative at Rs -125.01 lakh due to a large increase in inventory (seeds) to Rs 990.63 lakh. Total assets surged to Rs 7,330.87 lakh primarily from biological assets/inventory. The company operates in seed cultivation with long-term lease arrangements. Statutory auditors issued an unmodified opinion, confirming the financial statements present a true and fair view. However, auditors flagged emphasis of matter on unconfirmed balances for trade receivables, trade payables, and advances given to growers, and inability to verify cash sales details to farmers.
Profit decline of 19% and negative operating cash flow are concerning despite positive net profit. Shareholders should note auditor warnings on unverified transactions and high inventory levels tied to seasonal seed business.